Clinical Study on the Safety of CNT-02 for TGCV and NLSD-M

Neutral Lipid Storage Disease With Myopathy (NLSD-M) Clinical Trial

Official title: Clinical Study on the Safety and Efficacy of Medium-chain Fatty Acid Capsules (CNT-02) for Primary Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Neutral Lipid Storage Disease With Myopathy (NLSD-M)

Status Terminated

Clinical Trial Summary

This study is planning to evaluate the safety and clinical efficacy of medium-chain fatty acid capsules (food-grade CNT-02) in subjects with primary triglyceride deposit cardiomyovasculopathy (TGCV) and neutral lipid storage disease with myopathy (NLSD-M) associated with adipose triglyceride lipase (ATGL) genetic defects.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Lipid Metabolism, Inborn Errors
• Metabolic Diseases
• Muscular Diseases
• Neutral Lipid Storage Disease With Myopathy (NLSD-M)
• Primary Triglyceride Deposit Cardiomyovasculopathy (TGCV)

• NCT number: NCT02830763
• Study type: Interventional
• Source: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
• Status: Terminated
• Phase: N/A
• Start date: September 5, 2016
• Completion date: January 2019